ERBB2 and breast carcinoma: According to the proteomic and genomic results obtained after Bozepinib treatment and considering the recent works relating HER2 positivity with CSC phenotype in breast cancer cells with high ALDH activity [45, 46], we decided to analyze the efficacy of Bozepinib over CSCs enriched subpopulations.